Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab
Abstract A 52‐year‐old man underwent pneumonectomy of the left lung for previously diagnosed primary spindle cell carcinoma (pT4aN1M0, stage III B) with programmed death‐ligand 1 expression (tumor proportion score ≥95%) and without epidermal growth factor receptor gene mutation and anaplastic lympho...
Main Authors: | Yoshiko Mizushina, Fumiyoshi Ohyanagi, Jun Shiihara, Motoko Nomura, Hiromitsu Ohta, Hisashi Oshiro, Hiroyoshi Tsubochi, Gen Kusaka, Yasuhiro Yamaguchi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14068 |
Similar Items
-
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
by: Randy F. Sweis, et al.
Published: (2018-04-01) -
Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
by: Natacha Dencker Trabjerg, et al.
Published: (2019-07-01) -
Pembrolizumab-Associated Hypoparathyroidism: A Single Case Report
by: Israa Mahmood, PharmD, et al.
Published: (2021-01-01) -
Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
by: Hao‐Chun Chang, et al.
Published: (2020-08-01) -
Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
by: Hideo Oishi, MD, et al.
Published: (2020-10-01)